Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer

Q4 Medicine
Z. Tomašević, Z. Tomašević, Z. Kovac, Z. Milovanović, D. Grujicic, R. Dzodic
{"title":"Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer","authors":"Z. Tomašević, Z. Tomašević, Z. Kovac, Z. Milovanović, D. Grujicic, R. Dzodic","doi":"10.17925/EOH.2015.11.01.36","DOIUrl":null,"url":null,"abstract":"We present a patient who first developed a distant metastatic site in the cerebellum during treatment for Her2 3+ locally advanced breast cancer (LABC). LABC was in complete remission at that time and isolated cerebellar metastasis was resected. The patient is still alive more than 135 months after LABC diagnosis, and more than 99 months after neurosurgery, and is still receiving trastuzumab without further progression or any toxicity. To the best of our knowledge, this is first report of such exceptional disease course for a patient with a predicted grave prognosis according to all prognostic parameters.","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"39 1","pages":"36"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Oncology and Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EOH.2015.11.01.36","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

We present a patient who first developed a distant metastatic site in the cerebellum during treatment for Her2 3+ locally advanced breast cancer (LABC). LABC was in complete remission at that time and isolated cerebellar metastasis was resected. The patient is still alive more than 135 months after LABC diagnosis, and more than 99 months after neurosurgery, and is still receiving trastuzumab without further progression or any toxicity. To the best of our knowledge, this is first report of such exceptional disease course for a patient with a predicted grave prognosis according to all prognostic parameters.
Her2 - 3+局部晚期乳腺癌小脑转移切除术后的长期生存率
我们报告了一位在治疗Her2 3+局部晚期乳腺癌(LABC)期间首次在小脑发生远处转移的患者。当时LABC完全缓解,并切除了孤立的小脑转移灶。该患者在LABC诊断后存活超过135个月,在神经外科手术后存活超过99个月,并且仍在接受曲妥珠单抗治疗,无进一步进展或任何毒性。据我们所知,这是根据所有预后参数预测严重预后的患者的这种特殊病程的第一次报告。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Oncology and Haematology
European Oncology and Haematology Medicine-Hematology
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信